What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
Petrasek, J
Caroline was working concurrently with her GP and endocrinologist, and experiencing ongoing symptoms including feeling very fatigued, heart palpitations, body tremors, hair loss, insomnia, heartburn, diarrhoea, an ongoing cough, swollen thyroid, sudden irritability, and mood swings
Plascencia-Villa, G
Your provider will customize your dosing schedule based on your response and tolerance
Other updates include instructions to consult healthcare providers about managing low blood sugar, and to call the Poison Help Line, consult a physician or go to the emergency room if you take too much Mounjaro
